drugset / Trial / NCT00154297

Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients

NCT00154297

Phase 4 Completed 139 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate if the delayed administration of everolimus could reduce the everolimus associated "anti-proliferative complications" (e.g. wound healing disorder) while maintaining efficacy, when compared to the immediate administration of everolimus in de novo renal transplant patients.

Timeline

Start
2005-06
Primary completion
2008-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule Oral

Indications

No indication recorded.